■颅内动脉瘤(IAs)仍然是具有挑战性的神经系统诊断,与显着的发病率和死亡率相关。对于破裂和未破裂的动脉瘤,有许多显微外科和血管内技术。对于这种脑血管病理学的最佳治疗选择,尚无明确的共识。动脉瘤,动静脉畸形,与行业和中风专家讨论了最佳实践和最有希望的方法来改善脑动脉瘤的管理。
■一组来自学术界的专家,工业,和联邦监管机构开会讨论最新的临床试验,临床前系统模型的科学研究,管理选项,筛查和监测,和有前途的新型设备技术,旨在改善IA患者的预后。
■动脉瘤,动静脉畸形,与工业和中风的慢性硬膜下血肿圆桌会议讨论专家建议结合人工智能来捕获连续的动脉瘤生长,确定破裂的预测因素,并预测破裂的风险,以指导治疗方案。共识强烈建议在全国范围内收集未破裂的IA射线照相图像的系统数据,以分析和开发破裂风险的机器学习算法。共识支持卓越中心在遗传学等领域进行临床前多中心试验,细胞组成,和放射性基因组学。光学相干层析成像和磁共振成像对比增强3T血管壁成像是有前途的技术;然而,需要更多的数据来定义他们在IA管理中的角色。破裂的动脉瘤最好在大体积中心进行治疗,这应该包括全面的病人管理与显微外科的专业知识,血管内手术,神经学,和神经重症监护.
■关于IA的临床和临床前研究以及科学研究应参与大批量中心,并在多中心合作中进行。通过合并人工智能以及国家放射学和生物学注册,可以增强IA诊断和监测的未来。学术中心之间的合作努力,政府监管机构,设备行业对于IA的适当管理和该领域的发展至关重要。
UNASSIGNED: Intracranial aneurysms (IAs) remain a challenging neurological diagnosis associated with significant morbidity and mortality. There is a plethora of microsurgical and endovascular techniques for the treatment of both ruptured and unruptured aneurysms. There is no definitive
consensus as to the best treatment option for this cerebrovascular pathology. The Aneurysm, Arteriovenous Malformation, and Chronic Subdural Hematoma Roundtable Discussion With Industry and
Stroke Experts discussed best practices and the most promising approaches to improve the management of brain aneurysms.
UNASSIGNED: A group of experts from academia, industry, and federal regulators convened to discuss updated clinical trials, scientific research on preclinical system models, management options, screening and monitoring, and promising novel device technologies, aiming to improve the outcomes of patients with IA.
UNASSIGNED: Aneurysm, Arteriovenous Malformation, and Chronic Subdural Hematoma Roundtable Discussion With Industry and
Stroke Experts suggested the incorporation of artificial intelligence to capture sequential aneurysm growth, identify predictors of rupture, and predict the risk of rupture to guide treatment options. The
consensus strongly recommended nationwide systemic data collection of unruptured IA radiographic images for the analysis and development of machine learning algorithms for rupture risk. The
consensus supported centers of excellence for preclinical multicenter trials in areas such as genetics, cellular composition, and radiogenomics. Optical coherence tomography and magnetic resonance imaging contrast-enhanced 3T vessel wall imaging are promising technologies; however, more data are needed to define their role in IA management. Ruptured aneurysms are best managed at large volume centers, which should include comprehensive patient management with expertise in microsurgery, endovascular surgery, neurology, and neurocritical care.
UNASSIGNED: Clinical and preclinical studies and scientific research on IA should engage high-volume centers and be conducted in multicenter collaborative efforts. The future of IA diagnosis and monitoring could be enhanced by the incorporation of artificial intelligence and national radiographic and biologic registries. A collaborative effort between academic centers, government regulators, and the device industry is paramount for the adequate management of IA and the advancement of the field.